About this visual
Seven additional obesity medicine updates highlighted at EASD 2026: survodutide, olatorepatide, trevogrumab, orforglipron, ABBV-295, KAI-4729, and ecnoglutide.
Sources & further reading
These updates come from different studies, populations, treatment durations, and phases of development. Results are not head-to-head comparisons.



